Study Finds IL-10 Autoantibodies in 3.5% of IBD Patients as Gene Variant Explains Risk
Updated
Updated · news.inbox.eu · Jun 15
Study Finds IL-10 Autoantibodies in 3.5% of IBD Patients as Gene Variant Explains Risk
3 articles · Updated · news.inbox.eu · Jun 15
Summary
A New England Journal of Medicine study of 4,909 patients found IL-10 autoantibodies in about 3.5% of people with Crohn's disease or ulcerative colitis, while none were detected in healthy individuals.
IL-10 normally restrains immune inflammation, and the autoantibodies appear to block that anti-inflammatory signal, offering a newly identified mechanism for uncontrolled gut inflammation in a subset of IBD patients.
All patients with those autoantibodies carried the HLA-DRB1*01:03 variant, tying a long-known genetic risk factor to a specific autoimmune pathway for the first time.
The findings could support blood tests to identify this subgroup and future treatments aimed at the autoantibodies or the cells producing them, advancing more personalized IBD care.
A 30-year-old genetic mystery is solved. Could this lead to the first personalized cure for inflammatory bowel disease?
With a specific IBD cause identified, can advanced therapies like CAR-T 'reboot' a patient's faulty immune system?
2026 IBD Breakthrough: Discovery of Anti-IL-10 Autoantibody Subtype and HLA-DRB1*01:03 Genetic Link Transforms Diagnosis and Treatment
Overview
In 2026, researchers uncovered a new subtype of Inflammatory Bowel Disease (IBD) by identifying neutralizing anti-IL-10 autoantibodies in certain patients. This means the immune system mistakenly attacks its own IL-10, a key molecule that controls inflammation, leading to the uncontrolled inflammation seen in IBD. The study also found a strong genetic link with the HLA-DRB1*01:03 marker, which makes some people more likely to develop these autoantibodies. This breakthrough connects a genetic risk to a specific autoimmune process, opening the door to more accurate diagnosis and targeted treatments for this unique group of IBD patients.